Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McDonnell

Showing results (281-290 of 374) with videos related to

Pageof 38
Sort By:
Oncogene|November 22, 2016
Cystine addiction of triple-negative breast cancer associated with EMT augmented death signalingX Tang, C-K Ding, J Wu, et al.
Endocrinology|March 6, 1999
The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestinsB L Wagner, G Pollio, P Giangrande, et al.
Endocrinology|April 1, 1997
Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergismK Ramamoorthy, F Wang, I C Chen, et al.
Molecular Cancer Therapeutics|December 12, 2025
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer ModelsJianhui Ma, Sayee Hegde, Masha Sergeeva, et al.
The Journal of Biological Chemistry|June 7, 2015
Pregnancy and Smoothelin-like Protein 1 (SMTNL1) Deletion Promote the Switching of Skeletal Muscle to a Glycolytic Phenotype in Human and MiceBeata Lontay, Khaldon Bodoor, Adrienn Sipos, et al.
Molecular Endocrinology (Baltimore, Md.)|August 26, 2015
Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-TerminusAlicia M Blessing, Sathya Ganesan, Kimal Rajapakshe, et al.
Communications Biology|October 2, 2018
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistanceJemilat Salami, Shanique Alabi, Ryan R Willard, et al.
Endocrinology|September 22, 2011
The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptorsErik R Nelson, Carolyn D DuSell, Xiaojuan Wang, et al.
Breast Cancer Research and Treatment|September 29, 2019
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacySuzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
The Journal of Biological Chemistry|December 2, 2016
Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerPeter B Alexander, Rui Chen, Chang Gong, et al.
Pageof 38

Showing results (281-290 of 374) with videos related to

Sort By:
Pageof 38
Oncogene|November 22, 2016
Cystine addiction of triple-negative breast cancer associated with EMT augmented death signalingX Tang, C-K Ding, J Wu, et al.
Endocrinology|March 6, 1999
The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestinsB L Wagner, G Pollio, P Giangrande, et al.
Endocrinology|April 1, 1997
Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells, and yeast-based estrogen receptor assays: no apparent synergismK Ramamoorthy, F Wang, I C Chen, et al.
Molecular Cancer Therapeutics|December 12, 2025
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer ModelsJianhui Ma, Sayee Hegde, Masha Sergeeva, et al.
The Journal of Biological Chemistry|June 7, 2015
Pregnancy and Smoothelin-like Protein 1 (SMTNL1) Deletion Promote the Switching of Skeletal Muscle to a Glycolytic Phenotype in Human and MiceBeata Lontay, Khaldon Bodoor, Adrienn Sipos, et al.
Molecular Endocrinology (Baltimore, Md.)|August 26, 2015
Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-TerminusAlicia M Blessing, Sathya Ganesan, Kimal Rajapakshe, et al.
Communications Biology|October 2, 2018
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistanceJemilat Salami, Shanique Alabi, Ryan R Willard, et al.
Endocrinology|September 22, 2011
The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptorsErik R Nelson, Carolyn D DuSell, Xiaojuan Wang, et al.
Breast Cancer Research and Treatment|September 29, 2019
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacySuzanne E Wardell, Alexander P Yllanes, Christina A Chao, et al.
The Journal of Biological Chemistry|December 2, 2016
Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerPeter B Alexander, Rui Chen, Chang Gong, et al.
Pageof 38